2025-03-12 11:18:56
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Tatva Chintan Pharma Chem Ltd Q2 FY23 consolidated net profit slides to Rs. 7.11 crores
Posted On : 2022-11-04 20:25:17( TIMEZONE : IST )
Tatva Chintan Pharma Chem Ltd has reported Consolidated financial results for the period ended September 30, 2022.
Financial Results (Q2 FY2023) - QoQ Comparison
The company has reported total income of Rs. 91.640 crores during the period ended September 30, 2022 as compared to Rs. 90.231 crores during the period ended June 30, 2022.
The company has posted net profit / (loss) of Rs. 7.112 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs. 9.797 crores for the period ended June 30, 2022.
The company has reported EPS of Rs. 3.21 for the period ended September 30, 2022 as compared to Rs. 4.42 for the period ended June 30, 2022.
| Financials | Q2 FY2023 | Q1 FY2023 | % Change |
| Total Income | ₹ 91.640 crs | ₹90.231 crs |  1.56% |
| Net Profit | ₹7.112 crs | ₹9.797 crs |  -27.41% |
| EPS | ₹3.21 | ₹4.42 | -27.38% |
Financial Results (Q2 FY2023) - YoY Comparison
The company has reported total income of Rs. 91.640 crores during the period ended September 30, 2022 as compared to Rs.126.860 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.7.112 crores for the period ended September 30, 2022 as against net profit / (loss) of Rs.32.412 crores for the period ended September 30, 2021.
The company has reported EPS of Rs.3.21 for the period ended September 30, 2022 as compared to Rs.15.02 for the period ended September 30, 2021.
| Financials | Q2 FY2023 | Q2 FY2022 | % Change |
| Total Income | ₹ 91.640 crs | ₹126.860 crs | -27.76% |
| Net Profit | ₹7.112 crs | ₹32.412 crs | -78.06% |
| EPS | ₹3.21 | ₹15.02 | -78.63% |
Financial Results (Half Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.181.871 crores during the 6 Months period ended September 30, 2022 as compared to Rs.235.016 crores during the 6 Months period ended September 30, 2021.
The company has posted net profit / (loss) of Rs.16.908 crores for the 6 Months period ended September 30, 2022 as against net profit / (loss) of Rs.55.558 crores for the 6 Months period ended September 30, 2021.
The company has reported EPS of Rs.7.63 for the 6 Months period ended September 30, 2022 as compared to Rs.26.66 for the 6 Months period ended September 30, 2021.
| Financials | Half Year Ended FY2023 | Half Year Ended FY2022 | % Change |
| Total Income | ₹181.871 crs | ₹235.016 crs | -22.61% |
| Net Profit | ₹16.908 crs | ₹55.558 crs | -69.57% |
| EPS | ₹7.63 | ₹26.66 | -71.38% |
Shares of Tatva Chintan Pharma Chem Ltd was last trading in BSE at Rs. 2486.15 as compared to the previous close of Rs. 2461.30. The total number of shares traded during the day was 1517 in over 502 trades.
The stock hit an intraday high of Rs. 2500.00 and intraday low of 2414.15. The net turnover during the day was Rs. 3715228.00.
